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Abstract
Background: The cyclin D1 (CCND1) and cyclin D3 (CCND3) are frequently co-overexpressed in pancreatic ductal
adenocarcinoma (PDAC). Here we examine their differential roles in PDAC.
Results: CCND1 and CCND3 expression were selectively suppressed by shRNA in PDAC cell lines with expression
levels of equal CCND1 and CCND3 (BxPC3), enhanced CCND1 (HPAC) or enhanced CCND3 (PANC1). Suppression of
cell proliferation was greater with CCND3 than CCND1 downregulation. CCND3 suppression led to a reduced level
of phosphorylated retinoblastoma protein (
Ser795p-Rb/p110) and resulted in decreased levels of cyclin A mRNA and
protein. A global gene expression analysis identified deregulated genes in D1- or D3-cyclin siRNA-treated PANC1
cells. The downregulated gene targets in CCND3 suppressed cells were significantly enriched in cell cycle
associated processes (p < 0.005). In contrast, focal adhesion/actin cytoskeleton, MAPK and NF B signaling appeared
to characterize the target genes and their interacting proteins in CCND1 suppressed PANC1 cells.
Conclusions: Our results suggest that CCND3 is the primary driver of the cell cycle, in cooperation with CCND1
that integrates extracellular mitogenic signaling. We also present evidence that CCND1 plays a role in tumor cell
migration. The results provide novel insights for common and differential targets of CCND1 and CCND3
overexpression during pancreatic duct cell carcinogenesis.
Background
In normal cells, growth factors and mitogenic signaling
stimulate the expression of D-cyclins and E2F activity to
drive G0/G1 to S phase cell cycle progression [1]. D-
cyclins bind to and activate CDK4/6, which phosphory-
late the retinoblastoma tumor suppressor protein (Rb)
leading to its inactivation and the release of the E2F
transcription factors and expression of genes critical for
cell cycle progression. In many human cancers, one or
more of these regulators for G1/S cell cycle transition
are often altered in their expression or function [2]. The
inactivation of the tumor suppressor p16 [3] and the
overexpression of cyclin D1 (CCND1) and/or cyclin D3
(CCND3) are common in pancreatic ductal adenocarci-
noma (PDAC). During multi-stage pancreatic duct cell
carcinogenesis, CCND1 overexpression occurred mainly
in late stage pancreatic intraepithelial neoplastic (PanIN)
lesions, while CCND3 and cyclin A (CCNA)
overexpression occurred earlier and at higher frequen-
cies [4]. In contrast to CCND1 and D3, which are often
differentially over-expressed in PDAC [5], CCND2
appears to play a role mainly in the proliferation of pan-
creatic islet b-cell [6], and its mRNA expression was
infrequently detected in PDAC and pancreatic cancer
cell lines [5,7]. We hypothesize that in PDAC, CCND1
and CCND3 have different regulatory effects on the Rb/
E2F complex leading to the transcription activation of
different target genes with global effects on the cell
cycle. Previous studies suggest that there are non-redun-
dant roles of D-cyclins by their various combinations
that associate with different biological contexts (e.g.
embryogenesis, growth and differentiation) as well as in
carcinogenesis [8]. Many factors or mechanisms may
contribute to the deregulation of D-cyclins in PDAC.
These include the enhanced expression of growth fac-
tors, including platelet derived growth factor (PDGF),
amphiregulin and transforming growth factor (TGF)-a
[5]. The induction of CCND1 has been associated with
enhanced activities of multiple signaling pathways
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NOTCH1/NF-B and sonic hedgehog [9-11]. It remains
unclear whether the transcriptional targets of D-cyclins/
Rb/E2F pathway are limited to regulators of the cell
cycle or if they also have activities on other pathways in
PDAC, including apoptosis, invasion and sensitivity to
anti-cancer agents. In this study, we have examined the
overlap and divergence of CCND1 and CCND3 targets
and putative functions in PDAC cell lines BxPC3,
HPAC and PANC1, including their roles in cellular pro-
liferation, senescence, migration and global gene tran-
scription. Levels of CCND1 or CCND3 were suppressed
by using shRNA expressing lentivirus in three pancreatic
cell lines, BxPC3, HPAC and PANC1, that expressed
differential D1/D3-cyclins. Effects on global gene tran-
script targets using microarray was examined in PANC1
cells transfected with either D1 or D3 cyclins siRNA.
The functional annotation, enrichment and relationship
of affected genes were identified using three publicly
available databases: Gene Ontology (GO), KEGG path-
ways, and the Interolog Interaction Database (I
2D), a
protein-protein interactions database.
Materials and methods
Cell lines and growth/senescence assays
Human pancreatic cancer cell lines, BxPC3, HPAC and
PANC1 were obtained from the American Type Culture
Collection (Manassas, VA). BxPC3 expressed relatively
comparable levels of CCND1 and CCND3. HPAC
showed differentially higher expression of CCND1 than
CCND3, while PANC1 expressed higher levels of
CCND3. Cell proliferation was measured by MTS assay
(Promega, Madison, WI) as recommended. The senes-
cence-associated b-galactosidase assay was performed as
described previously [12].
Viral vector constructs
DNA oligonucleotides were generated, annealed and
ligated into lentiviral vectors plko.YFP or plko.1puro as
described previously [13]. The first set of siRNA
sequences (Dharmacon Research Inc., Lafayette, CO),
CCND1 (GTTCGTGGCCTCTAAGATGAA; shD1_1)
and CCND3 (ACAGAATTGGATACATACACC;
shD3_1) were subcloned into pLKO.YFP vectors. The
second set of siRNA sequences, CCND1 (CCTGAG-
GAGCCCCAACAACTT; shD1_2) and CCND3
(TAGATGGCTCCTCTCAGTACT; shD3_2) were sub-
cloned into the pLKO.puro vector. A control shRNA
sequence was adopted from a non-silencing control
siRNA sequence (TTCTCCGAACGTGTCACGT) (Qia-
gen Inc., Mississauga, ON). Lentiviruses preparation and
subsequent transduction was performed as described
previously [14]. Vector expressing CCND1, pBMN-
CCND1, was constructed by inserting full-length
CCND1 cDNA (BamHI/XhoI) into pBMN-I-GFP (Garry
Nolan laboratory, Stanford University, CA).
Western blot analysis
Immunoblotting was performed using whole protein
extracts from exponentially dividing cells, and probed
with the following antibodies against cyclin D3 (BD
Biosciences, St. Jose, CA), cyclin D1 (BD Biosciences),
Rb (Cell Signalling Technology (CST)), p-Rb (Ser780,
Ser795 and Ser807/811, CST), cyclin A (BD Bios-
c i e n c e s ) ,C d k 4( C S T ) ,C d k 6( C S T ) ,E r k( C S T ) ,p - E r k
(Thr202/Tyr204; CST), Akt (CST), p-Akt (Ser473; CST),
GAPDH (Abcam), and secondary mouse or rabbit con-
jugated IgG-horseradish peroxidase (CST). Each blot
was repeated at least three times. Densitometry was per-
formed using the ImageJ software to measure the inte-
grated intensity and band size. Levels were calculated
relative to the GAPDH standard control on each blot.
Transwell migration and invasion assays
Trypsin dissociated cells (5 × 10
4) were resuspended in
medium containing 2% bovine serum albumin and
added on to the top chambers of 24-well Transwell
plates coated with 7.5 μgc o l l a g e nt y p eI V( C NI V )f o r
migration assay and 5 μg/mL fibronectin containing
medium was added to the bottom chambers. Cells were
incubated for 48 hours at 37°C in a humidified incuba-
tor, then fixed with 0.1% glutaraldehyde-PBS for 20
minutes, rinsed with double-distilled water, and stained
with 0.2% crystal violet for an hour. Filters were washed
thoroughly with double-distilled water and non-motile
cells on top of filters were removed using cotton swabs.
Microarray transcriptional profiling
Cyclin D dependent gene expression was determined in
PANC1 cells transfected with D1- or D3-cyclin siRNA
obtained as SMARTpool duplexes, or non-specific
siRNA as a control (Dharmacon Products, Thermo
Scientific, Lafayette, CO) as described previously [4].
Lentiviral transduced cells were omitted from this assay
due to possible transcriptional effects dependent on
integration of lentiviral genes [15]. RNA was isolated 72
hours post transfection, and analyzed using an Affyme-
trix U133 plus 2 microarray (Santa Clara, CA). The raw
microarray data were pre-processed using the RMAex-
press v0.3 and values were log2-transformed [16].
Expression levels from D1- or D3-cyclin siRNA-treated
cells were compared to levels from non-specific siRNA
control cells, and filtered to include probe sets that were
altered at least 2-fold. Probe sets were annotated against
UniGene (build Hs.197) using BLASTN [17] or Gen-
eAnnot tool http://bioinfo2.weizmann.ac.il/geneannot/
[18]. Annotated probe sets were then matched with an
Entrez Gene ID, Gene Symbol and Gene Name using
the Entrez Gene database of 2006-11-28 and SwissProt
ID (Build 51.5). Analysis was completed with reference
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termed “target genes”.
Reverse transcription and quantitative PCR (RT-QPCR)
RT-QPCR was used to validate microarray results of a
subgroup of gene targets. RT was completed at 42°C
with SuperScript II RNase H
- reverse transcription kit
(Invitrogen, Burlington, ON, Canada). QPCR was per-
formed with 10 ng of the first-strand cDNA synthesis
mixture as a template and individual primer sets [See
Additional file 1] using a Stratagene MX3000P instru-
ment (La Jolla, CA). Primers were designed using pub-
licly available primer bank [19].
Gene expression levels in the samples were calculated
relative to control using the comparative CT method
[20]: ΔΔCT = ΔCT sample - ΔCTc o n t r o l ,f o l dc h a n g e=2
-
ΔΔCT. The geometric mean of ribosomal protein S13, b-
actin, TATA binding protein and b-2-microglobulin
were used to normalize the expression data (ΔCT).
Functional annotation of gene expression data
To systematically annotate and predict biological pro-
cesses and pathways of target genes affected by the sup-
pression of cyclin D levels we employed three strategies:
1) GO term annotation and enrichment analysis using
GoMiner (http://discover.nci.nih.gov/gominer/GoCom-
mandWebInterface.jsp, version 2007-06) [21]; 2) KEGG
pathways annotation using the selection of 38 human
cancer and signaling specific KEGG pathways (ftp://ftp.
genome.jp/pub/kegg/; downloaded on 2007-07-30) [22];
3) target genes matching to protein-protein interactions
(PPIs) in I
2D (Interolog Interaction Database) v1.7
http://ophid.utoronto.ca/i2d[23].
GoMiner was used to determine whether the target
genes as well as the corresponding proteins in PPI net-
works showed enrichment in certain GO biological pro-
cesses. Enrichment is defined as the proportion of
changed genes in the category relative to the expected
proportion for the entire microarray. Significance was
tested using one-sided Fisher’s exact test and the false-
discovery rate (FDR) threshold was set at 0.05, with
1000 randomizations [24].
Additional functional annotation was performed using
a selection of 38 biological signaling and disease-related
KEGG pathways. To assess enrichment for specific
KEGG pathways representation in the target genes the
proportion of target genes was compared with propor-
tion of genes expected from the entire gene set on U133
Plus 2.0 microarray using Fisher’s exact test. Obtained
p-values were corrected for multiple testing of the 38
KEGG pathways.
Experimental PPI networks were generated by query-
ing the I
2D database with the target genes to obtain cor-
responding proteins and their immediate interacting
partners (i.e., depth of 1). Relationships between the
interacting proteins were added to the same network
(depth of 1 plus), resulting in PPI networks with 576
proteins and 4557 interactions for CCND3 uniquely
deregulated genes, 1362 proteins and 12135 interactions
for CCND1 uniquely deregulated genes, and 289 pro-
teins and 1763 interactions for common genes deregu-
lated in both CCND1/CCND3 siRNA, used in
subsequent analyses. The proteins in PPI networks were
annotated with GO biological processes and tested for
enrichment using GoMiner as described above. Signifi-
cant KEGG pathways were determined for target genes
and their interacting proteins in PPI networks by testing
their proportions against expected proportions estimated
from 1000 randomly-generated PPI networks obtained
by querying a subset of I
2D for genes represented on
Affymetrix U133 Plus 2.0 chip, with the same number
of proteins as cyclin D1/D3 deregulated target genes
matched in I
2D (81 for cyclin D1 deregulated target
genes in PPI, 37 for cyclin D3 and 21 for deregulated
target genes in common to cyclin D1/D3). The Student’s
t-test was then used to compare the proportion in the
experimentally determined PPI network against the dis-
tributions in random networks, as previously described
[25]. Obtained p-values were corrected for multiple test-
ing of the 38 KEGG pathways used for annotation. PPI
networks were annotated, visualized and analyzed using
NAViGaTOR v2.0 http://ophid.utoronto.ca/navigator/
[26].
Results
Effects of D-cyclin downregulation on G1-S cell cycle
regulators
The YFP transduction marker was detected at 48 hours
in >90% of cells following transduction with lentiviruses
containing CCND1 shRNA (shD1_1), CCND3 shRNA
(shD3_1) or non-specific shRNA (shNS) in all three
pancreatic cancer cell lines BxPC3, HPAC and PANC1
(Figure 1A insert). The transduction using shD1_1
downregulated CCND1 mRNA expression by 79% to
92% and shD3_1 downregulated CCND3 mRNA expres-
sion by 67% to 89% in all three cell lines (Figure 1A).
Consistent with these effects, CCND1/D3 protein levels
were significantly decreased (p < 0.01) as shown in the
representative PANC1 cell line (Figure 1B).
CCND1 suppression significantly increased CCND3
RNA and protein levels (Figure 1B and 1C), but CCND3
suppression did not result in a similar compensatory
upregulation in the CCND1 levels. Suppression of
CCND3 was also associated with decreased Rb and p-Rb
(Ser795) levels (p < 0.01), but not pRb(Ser780) or pRb
(Ser807). In contrast, suppression of CCND1 resulted in
significant decrease in p-Rb(Ser807) levels (p < 0.01),
but not pRb(Ser780) or pRb(795) (Figure 1B: Additional
File 2). Suppression of CCND3 but not CCND1
decreased the mRNA and protein levels of cyclin A
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Page 3 of 15Figure 1 Cyclin D1/D3 suppression effects on cell cycle and proliferation. (A) The expression of lentiviral shD1_1 or shD3_1 decreases the
mRNA of D1- or D3-cyclin, respectively in BxPC3, HPAC and PANC1 cells. Bars represent medians. The insert is a representative image of
shNS_YFP transduced PANC1 cells (insert). (B) Immunoblots show effects of shD1_1, shD3_1 or non-specific shNS on cell cycle-specific proteins
D-cyclins, Rb, cyclin A (CCNA) and equal loading control GAPDH in PANC1 cells. (C) Differential effects of shD1_1 or shD3_1 expression on
mRNA levels of the D-cyclins and cyclin A in PANC1 cells. (D) Proliferation was decreased in all three cell lines over a period of 4 days after 2
days transduction with shD1_1 or shD3_1 compared with shNS. Values are mean ± standard error. An asterisk (*) designates significant
differences between test and control samples (p < 0.001, two-way RM ANOVA and Bonferroni posttests). Significantly different tested pairs are
designated by brackets.
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1C). The protein levels of Cdk4/6 remained unchanged
in either shD1_1 or shD3_1 relative to shNS treated
PANC1 cells (Figure 1B).
D-cyclin dependent proliferation
Cell proliferation was similarly suppressed by downregu-
lation of both CCND1 and CCND3 (p < 0.001) in all
three cell lines. The shD3_1 achieved a slightly but sig-
nificantly greater suppression after 4 days in BxPC3 that
expresses comparable levels of both D-cyclins (Figure
1D). Suppression of the CCND3 induced a significant
greater loss of proliferation (p < 0.001) than CCND1
suppression in both the HPAC cells that express higher
CCND1, and in PANC1 cells that express higher
CCND3. Therefore, regardless of the basal CCND1/D3
expression levels in the PDAC lines, proliferation was
inhibited to a greater extent in cells transduced with
shD3_1 compared with shD1_1. This decrease in prolif-
eration was associated with an onset of cellular senes-
cence. A loss of the YFP transduction marker occurred
5 to 20 days post transduction without the induction of
apoptosis [see Additional file 3]. At 20 days, YFP-labeled
cells were larger and flatter (Figure 2A), and represented
approximately 20% of total cell population (Figure 2B).
These larger cells stained positive for b-galactosidase, a
marker of cellular senescence (Figure 2C). Growth of
PANC1 cells in vivo resulted in tumor without the YFP
marker following subcutaneous injections in SCID mice
with shD1_1 or shD3_1 infected cells, suggesting that
cells with stable suppression of either D1- or D3-cyclins
did not proliferate or survive (data not shown).
T oc o n f i r mt h a tr e s u l t sw i t hs h D 1 _ 1o rs h D 3 _ 1w e r e
specific to shRNA expression and not due to off-target
effects, different target sequences of shRNA against the
D-cyclins (shD1_2 and shD3_2 in pLKO.puro vectors)
were tested in PANC1 cells. Similar results were
obtained showing that CCND3 suppressed cells were
growth inhibited to a greater extent than the CCND1
suppressed cells [See Additional file 4].
Global transcriptome changes associated with D-cyclin
suppression
Transcriptional profiling was performed on PANC1 cells
transfected with siRNA against CCND1, CCND3, or a
non-specific control (NS). Our dataset included 189
probe sets corresponding to 165 deregulated genes that
were altered at least two-fold compared to the control
and associated with CCND1 suppression, and 107 probe
sets corresponding to 106 deregulated genes related to
CCND3 suppression. The cyclin D1/D3 datasets shared
36 probe sets corresponding to 34 deregulated genes
[see Additional file 5, Table S2A]. Probe sets and their
corresponding deregulated genes unique to either cyclin
D1 or D3 suppression are shown in Additional file 5
(Table S2B and S2C, respectively).
Common D-cyclin regulated genes
D-cyclins co-regulated target genes potentially are genes
that were downregulated as a result of either D1- or
D3-cyclin suppression (Table 1). Listed genes are from
largest to smallest decreases in expression levels unique
to CCND1 or CCND3 siRNA treatment, and their
shared effects. Changes in gene expression of selected
downregulated genes identified by microarray analysis
were also similarly observed using RT-QPCR analysis in
both CCND1 and CCND3 siRNA treated PANC1 cells
(Figure 3A and Figure 3B). These targets were primarily
selected as they have also been shown to be deregulated
in several publicly available profiling databases of PDAC
[27-32]. To determine if these targets are PANC1 cell
specific, we also assessed their expression in shD1_1
(Figure 3A) and shD3_1 (Figure 3B) treated BxPC3 and
HPAC lines. The expression levels of selected genes are
more similar between PANC1 and BxPC3 cells than to
HPAC when either D1- or D3-cyclin was suppressed.
To explore the potential biological functions of the
target genes/proteins, annotations are derived from GO
biological processes, KEGG pathways and relevant pro-
tein-protein interaction (PPI) networks from I
2D[ S e e
Additional file 6]. Potential functions of the shared 34
deregulated cyclin D1/D3 target genes and their inter-
acting proteins are evident from GO biological processes
analysis where a significant enrichment (p-value < 0.05)
was found in a diverse set of biological processes,
including Wnt signaling, and processes involving mem-
brane and vesicle biogenesis and transport [see Addi-
tional file 7, Table S4A].
Cyclin-D3-regulated genes
CCND3-specific downregulated target genes annotated
to GO biological processes were significantly enriched
for cell cycle (9/24 genes, p-value ≤ 0.004) and pro-
grammed cell death/cell death processes (8/24 genes, p-
value ≤ 0.004) [see Additional file 7, Table S4B]. These
functions were enriched approximately 6-fold compared
to the expected proportion of genes annotated for those
functions in the gene population represented on the
entire microarray. Five genes were commonly downre-
gulated in both processes, CDKN1A, CUL3, GADD45B,
PDCD4 and PLAGL1. Downregulated genes BCAT1,
DBF4, MAP9 and SKP2 were specific for cell cycle func-
tion, while TIA1, RAB27A and IFIH1 were specific for
programmed cell death function. The gene targets and
their immediate interacting proteins in PPI networks
were also consistently annotated by the cell cycle path-
way (Figure 4), which included factors unique and com-
mon to GO terms [see Additional file 7, Table S4C] and
KEGG pathways [see Additional file 8]. Further, the
deregulated target genes and their interacting proteins
are also associated with Notch (p-value = 0.0011),
induction of apoptosis (p-value = 0.0024) [see
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[see Additional file 8] pathways.
Cyclin D1 regulated genes
CCND1-specific deregulated target genes did not show
significant enrichment of particular biological processes
as determined by GO terms and KEGG pathways (p-
value > 0.05). However, the analysis of the deregulated
t a r g e tg e n e sa sw e l la st h e i rinteracting proteins from
PPI networks did show that CCND1 suppression
deregulated potentially cell cycle and cell death pro-
cesses [see Additional file 7, Table S4D]. Additional
f u n c t i o n st h a tw e r er e v e a l e di nt h i sa n a l y s i si n c l u d e d
a c t i nc y t o s k e l e t o no r g a n i z a t i o na n dN F - B cascade as
annotated by GO biological processes [see Additional
file 7, Table S4D], and focal adhesion and MAPK factors
as annotated by KEGG pathways [see Additional file 8],
suggesting that CCND1-specific processes are linked
closer to external stimuli and signal transduction.
Figure 2 D-cyclin suppression induces senescence. (A) Representative images show transduced YFP expressing PANC1 cells, 20 days post-
transduction. Arrows indicate YFP cells of large senescent-like morphology that were quantified (B), bars are mean ± standard error. (C) A
representative image shows that larger cells of shD3_1 transduced PANC1 display senescence associated b-galactosidase activity (arrows). Scale
bars designate 20 μm.
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gets and interacting proteins that are unique and com-
mon to GO and KEGG annotations in CCND1-
supressed cells are mapped in a PPI network (Figure
5A). To test if cyclin D1 has a function in this network,
we assessed the effects of shD1_1 and shD3_1 on the
migration activity of BxPC3 and HPAC cells through
the extracellular matrix component collagen type IV
coated membranes. PANC1 was excluded from this ana-
lysis due to its very low mobility through collagen (data
not shown). Suppression of CCND1 significantly
decreased migration activity in BxPC3 (28 ± 3%) and
HPAC (49 ± 8%) cells relative to shNS controls (p <
0.05; Figure 5B). The suppression of CCND3 also led to
a significant decrease in migration activity relative to
shNS in BxPC3 (55 ± 7%, p < 0.05; Figure 5B), however
this effect was significantly lower than the effect of
cyclin D1 knockdown (p < 0.05; Figure 5B). In contrast,
while both shD3_1 and shD1_1 suppressed (52 ± 7%)
similarly the migration activity of HPAC cells (p < 0.05;
Figure 5B), these levels were less than that observed in
shD1_1 treated BxPC3. Importantly, the overexpression
of CCND1 (Figure 5C) in PANC1 cells significantly
increased their migration activity through collagen type
IV coated membranes (p < 0.05; Figure 5D).
Deregulated MAPK and NFB/I-B kinase targets and
interacting proteins that are unique and common to GO
and KEGG annotations in CCND1-suppressed cells are
also mapped in a PPI network (Figure 6A). When ERK,
a downstream target of the MAPK signaling cascade
was inhibited using UO126, a MEK inhibitor, the
CCND1 levels were 13 ± 1% in BxPC3 (p < 0.01) and
28 ± 10% in PANC1 cells relative to shNS controls (Fig-
ure 6B; Additional File 9). While CCND3 protein levels
remained unchanged in UO126 treated BxPC3 and
PANC1 cells, the CCND3 levels were 26 ± 7% in
Figure 3 Levels of gene expression changes were similar using either microarray or quantitative PCR (QPCR) assays. Comparison was
performed on 20 target genes that were downregulated in PANC1 cells treated with (A) CCND1 siRNA or (B) CCND3 siRNA. A subset of genes
was selected to determine expression levels in all three cell lines (PANC1, BxPC3 and HPAC) after suppression of CCND1 or CCND3.
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Cyclin D1 down regulated genes Cyclin D3 down regulated genes Common Cyclin D1 and D3 down regulated genes
Fold change
with D1 siRNA
Gene
Symbol
UniGene Fold change
with D3 siRNA
Gene
Symbol
UniGene Fold change
with D1 siRNA
Fold change
with D3 siRNA
Gene
Symbol
UniGene
0.1626 USP24 Hs.477009 0.3528 DHX40 Hs.29403 0.105 0.4495 SLC18A2 Hs.369009
0.2594 UHMK1 Hs.127310 0.3879 FNDC3B Hs.159430 0.3169 0.4886 TncRNA Hs.523789
0.2817 PDZD8 Hs.501149 0.3888 GPR180 Hs.439363 0.3967 0.4357 PRDX2 Hs.432121
0.3076 HIPK3 Hs.201918 0.3888 LOC144874 Hs.439363 0.4124 0.4593 LOC400043 Hs.19193
0.336 MALAT1 Hs.642877 0.3939 SLC39A6 Hs.79136 0.4233 0.4004 ELOVL6 Hs.412939
0.3422 GPR137B Hs.498160 0.405 C1orf52 Hs.26226 0.4569 0.4731 PTBP2 Hs.591430
0.3425 SIKE Hs.632428 0.4093 LIMS3 Hs.535619 0.4592 0.4352 AHNAK Hs.502756
0.3558 LIN28B Hs.23616 0.4093 LOC440895 Hs.535619 0.4615 0.4785 LOC348840 Hs.512227
0.3661 MLLT11 Hs.75823 0.4205 C14orf138 Hs.558541 0.4795 0.484 FAM70A Hs.437563
0.3673 GALNT7 Hs.127407 0.421 CYP26B1 Hs.91546 0.4798 0.4904 PPP2R1B Hs.584790
0.3739 PRMT2 Hs.154163 0.4223 GADD45B Hs.110571 0.4901 0.4935 CA5BL Hs.532326
0.3742 ARL6IP6 Hs.516468 0.4243 DBF4 Hs.485380 0.5116 0.4906 C9orf5 Hs.621479
0.3933 CNOT6 Hs.157606 0.4287 SYT11 Hs.32984
0.3959 ATG12 Hs.264482 0.4288 SLC35F3 Hs.158748
0.4142 WDR17 Hs.532056 0.4293 CRLF3 Hs.370168
0.4191 PAQR3 Hs.632591 0.4334 PPP2CB Hs.491440
0.4208 PDGFA Hs.645488 0.4361 RAB27A Hs.493512
0.4296 LRRC58 Hs.518084 0.4433 TMEM140 Hs.567530
0.4305 SCML1 Hs.109655 0.446 PDCD4 Hs.232543
0.4315 RBM6 Hs.596224 0.4534 HYMAI Hs.444975
0.4405 FAM55C Hs.130195 0.4534 PLAGL1 Hs.444975
0.4416 CPOX Hs.476982 0.4537 ARMC8 Hs.266826
0.4431 PGM2 Hs.23363 0.4558 IFIH1 Hs.163173
0.446 PRPF40A Hs.591637 0.4585 SKP2 Hs.23348
0.4463 CMTM4 Hs.643961 0.4601 AFG3L1 Hs.534773
0.4467 FBXO27 Hs.187461 0.4607 BEX2 Hs.398989
0.4484 HOXB8 Hs.514292 0.4612 ARL6IP5 Hs.518060
0.4548 DLD Hs.131711 0.4614 MBOAT1 Hs.377830
0.4554 LOC205251 Hs.128499 0.4685 SLC39A6 Hs.79136
0.4578 LGALS8 Hs.4082 0.4731 MAP9 Hs.61271
0.4622 E2F7 Hs.416375 0.474 GPRC5B Hs.148685
0.4644 FAM116A Hs.91085 0.4786 GABARAPL3 Hs.592014
0.4668 HRB Hs.591619 0.4798 C8orf44 Hs.545401
0.468 PXK Hs.190544 0.4798 PTTG3 Hs.545401
0.4686 CHPT1 Hs.293077 0.4798 SGK3 Hs.545401
0.4712 USP45 Hs.143410 0.486 CDKN1A Hs.370771
0.4718 EIF1AX Hs.522590 0.4873 SERBP1 Hs.530412
0.4746 FDFT1 Hs.593928 0.4902 IQCK Hs.460217
0.4762 C10orf32 Hs.34492 0.4929 DLL1 Hs.379912
0.478 ETNK1 Hs.29464 0.4948 KDELC1 Hs.408629
0.4823 UBE2Q1 Hs.607928 0.4959 C12orf57 Hs.591045
0.4898 FRAT2 Hs.140720 0.4967 IFIT2 Hs.437609
0.4918 TMEM97 Hs.199695 0.4969 BCAT1 Hs.438993
0.4926 EML4 Hs.593614 0.4973 CUL3 Hs.372286
0.4938 ATP11C Hs.88252 0.4992 ANP32E Hs.603000
0.4979 TMSL8 Hs.56145 0.4998 TIA1 Hs.516075
0.4992 PAK3 Hs.390616
Dowregulated gene targets in D-cyclin suppressed cells, unique to cyclin D1, cyclin D3, and shared targets of either D1- or D3-cyclin suppression. Genes are
listed in order of ascending fold change.
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Page 8 of 15UO126 treated HPAC cells (p < 0.01; Figure 6B; Addi-
tional File 9) relative to the shNS control. In contrast to
ERK, the inhibition of Akt signalling with 60 nM wort-
mannin (WM) had no significant effects on the protein
levels of both D1 and D3-cyclins in all three cell lines.
To test if Erk signaling has a role in cell migration of
PDAC cells we assessed the migration of BxPC3 and
HPAC cells through collagen in the presence of MEK
inhibitor UO126. Compared to the untreated control,
UO126 inhibited the migration of BxPC3 and HPAC
cells through collagen by 93% and 53% respectively (p <
0.01; Figure 6C).
Discussion
The differential combination of the three D-cyclins (D1,
D2 and D3) suggests that they could function in a coop-
erative, redundant or distinct manner depending on the
biological context [33]. Our results showed that the loss
in expression of cyclin D1/D3 inhibited proliferation
and resulted in a decrease of the hyperphosphorylated/
inactivated Rb in PDAC cells, consistent with the exist-
ing concept that D-cyclins drive proliferation in cancer
cells [34]. We further demonstrated that D1/D3-cyclins
have additional roles, which may cooperate to enhance
malignant progression in pancreatic duct cell
carcinogenesis.
Inhibition of cell proliferation was greater in CCND3
than CCND1 downregulated cells immediately after
shRNA transduction in HPAC and PANC1 cells, and
also within 4 days after transduction into BxPC3, irre-
spective of the differences in basal CCND3 and CCND1
gene expression levels. An upregulation of CCND3
expression in CCND1 suppressed cells suggests a com-
pensatory mechanism possibly attributing to the lesser
Figure 4 Cyclin D3-specific deregulated genes and their functional networks. A protein-protein interaction (PPI) network shows proteins
corresponding to deregulated genes in CCND3 siRNA-treated cells and their interacting proteins obtained from I
2D protein interaction database
ver. 1.7 [23] annotated to the cell cycle process. Target genes/proteins whose expression is up-regulated or down-regulated (up/downward
triangle nodes, respectively) by at least 2-fold compared with control and their interacting proteins (round nodes) are annotated by either GO
cell cycle term (pink nodes, GO:0007049), KEGG cell cycle pathway (green nodes, KEGG hsa4110), common to both annotations (orange nodes),
or none of the above (grey nodes). Target nodes positions reflect their interactions with cell cycle annotated nodes (colored), connecting
directly to the annotated nodes or via intermediate node(s). Nodes and edges not directly connecting target nodes to pathway-annotated
interacting nodes were faded out to reduce network complexity. This network incorporates 37/72 deregulated genes from CCND3 siRNA-treated
cells; 36 proteins form a single connected network. A single target IFIT2 was identified in I
2D, but did not connect to the other nodes at the
depth of the presented network. PPI network analysis was done using NAViGaTOR 1.13 ([26]; http://ophid.utoronto.ca/navigator).
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Page 9 of 15Figure 5 Cyclin D1-specific deregulated genes are connected to focal adhesion and actin skeleton network. (A) The PPI network shows
81 proteins corresponding to deregulated genes from CCND1 siRNA-treated cells by at least 2-fold compared with control and their interacting
proteins obtained from I
2D database constitute a single connected network with 79 proteins. Target nodes positions reflect their interactions
with pathway-annotated nodes (colored), connecting directly to the annotated nodes or via intermediate node(s). Nodes and edges not directly
connecting target nodes to pathway-annotated interacting nodes were faded out to reduce network complexity. Target genes/proteins whose
expression is up-regulated or down-regulated (up/downward triangle nodes, respectively) and their interacting proteins (round nodes) are
annotated by focal adhesion pathway (blue nodes, KEGG hsa4510), actin cytoskeleton organization and biogenesis (green nodes, GO:0030036),
common proteins to both annotations (turquoise nodes), or none of the above (grey nodes). Two proteins, FLRT2 and TMPRSS2, are identified in
I
2D, but did not connect to the other nodes at depth of the presented network. (B) Collagen type IV migration is decreased in BxPC3 and HPAC
cells stably expressing shD1_1 compared with control shNS. Representative plots are shown of two repeated experiments completed in
duplicate. A significant difference, p < 0.05, in migration between treatments shNS and shD1 or shD3 for each cell line is indicated with an
asterisk (*), or between a pair of treatments was indicated with a bracket and asterisks. (C) mRNA levels of CCND1 in PANC1 cells transfected
with pBMN compared to pBMN_CCND1 vector are significantly increased, p < 0.05 (*). (D) Collagen type IV migration is significantly increased, p
< 0.05, in PANC1 cells upon transient overexpression of CCND1. PPI network analysis was done using NAViGaTOR 1.13 ([26]; http://ophid.
utoronto.ca/navigator).
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Page 10 of 15effect of CCND1 knockdown on PANC1 cell prolifera-
tion. This is consistent with previous report that
CCND3 partially compensates for loss of CCND2 in
mouse B-lymphocytes by Rb phosphorylation on Cdk4
specific sites [35] Additionally, the remaining D-cyclins
can increase when a tissue-specific D-cyclin is elimi-
nated during early murine embryonic development [36].
However, our results demonstrate that such compensa-
tory mechanism might be CCND1 specific, as it was
absent in CCND3-suppressed PANC1 cells.
The immediate response of CCND3 suppression
involved the significant loss of Rb hyperphosphorylation
and a putative gain of Rb function. Given that cyclin D
partners, Cdk4 and Cdk6, remain unchanged as a result
of either CCND1 or CCND3 knockdowns, it is likely
that CCND1 and/or CCND3 are rate limiting for Cdk
activity in PANC1 cells. Decreases in phosphorylated-Rb
has been associated with the knockdowns of CCND1
[37,38], specifically the loss of phosphorylation at Ser780
on Rb has been associated with CCND1/CCND3 pro-
teolysis and growth arrest in cancer cells [39]. We have
demonstrated that CCND3-specific loss of phosphoryla-
tion at Ser795 on Rb led to a decrease in cyclin A
expression, suggesting an effective loss of E2F transcrip-
tion activity. Due to an overlap in the activity of D-
cyclins-cdk4/6 complexes on the 16 putative phosphory-
lation sites of Rb, specific effects of phospho-Rb profiles
on physiological outcome remains unclear [40]. Evi-
dence from the study of diverse cell types shows that
patterns of Rb phosphorylation [41] and the resulting
Figure 6 Cyclin D1-specific deregulated genes are connected to MAPK pathway. (A) PPI network shows target proteins and their
interacting partners annotated by the MAPK pathway (brown nodes, KEGG hsa4010), NFB/I-B kinase cascade (blue nodes, GO:0007249),
common proteins to both annotations (purple nodes), or none of the above (grey nodes). (B) Immunoblots show responses of cyclin D1/D3
levels to the inhibition of ERK activity with UO126 (UO) for 18 hours, and inhibition of PI3K/Akt activity with wortmannin (WM) for 4 hours.
GAPDH levels show equal protein loading. (C) The migration through CN IV of untreated control and UO126-treated BxPC3 and HPAC cells are
shown from two repeated experiments completed in duplicate. An asterisk designates a significant difference (p < 0.05) between treated cells
and the respective control cells.
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Page 11 of 15effects on cell cycle are associated with selective D-type
cyclin response to different mitogenic modes regulating
cell growth (mass accumulation) [42], proliferation [43],
and cell differentiation [41]. Cyclin D1 expression, the
most studied D-cyclin in cancer cell has been associated
with anchorage-independent growth, tumorigenicity,
angiogenesis, hypoxia response and resistance to che-
motherapeutic agents [44]. Our data suggest that
CCND1 and CCND3 associate with unique Rb phos-
phorylation patterns to mediate a differential effect on
global gene transcription in pancreatic cancer cells.
The number of deregulated cell cycle genes increases
progressively during multi-stage duct cell carcinogenesis.
The inactivation of p16
INK4A has been reported in vir-
tually all PDACs [45]. As the main function of p16 is to
inhibit the interaction/activity of CCND1 and CDK4/6,
a loss of p16 would result in unrestrained activation of
the latter, constitutive phosphorylation of Rb and activa-
tion of E2F transcription factor. Nevertheless, we and
others have reported that despite the putatively ubiqui-
tous loss of p16, CCND1 expression is elevated in 30-
50% of PDAC and specifically, we showed that CCND3
is elevated in almost all PDAC [4,46]. Our present
results provide important novel insight suggesting that
despite the inactivation of p16, CCND3 plays a major
role in driving cell cycle progression in PDAC, equal to
or even greater than CCND1. This difference on cell
cycle effects between CCND1 and CCND3 was also
revealed by our PPI network analysis, which shows that
CCND3 regulated genes interact predominantly with
cell cycle regulatory genes.
We have also demonstrated that prolonged downregu-
lation of CCND1 or CCND3 in PANC1 cells induced
cellular senescence. The cellular senescence can be trig-
gered in response to a variety of stresses activated
mainly by the p53 and Rb pathways [47]. Mutation of
p53 and homozygous deletion of p16
INK4a result in
PANC1 cells relying on the Rb/cyclinD/Cdk4 pathway
for the cell cycle control. Given that the destabilization
of CCND1 and CCND3 is a necessary step in induction
of growth arrest in PDAC cells [48] it is possible that
the inactivation of cyclin D proteins in PANC1 cells
resulted in a protracted hyperphosphorylation of Rb and
binding to E2F family proteins, eventually leading to cel-
lular senescence.
The results of our microarray and PPI analysis suggest
that genes of non-cell cycle pathways, including focal
adhesion, MAPK and NFB are regulated potentially by
CCND1. We have shown that cell migration through
collagen type IV was significantly inhibited with CCND1
suppression in BxPC3 and HPAC cells. Furthermore,
PANC1 migration was increased following overexpres-
sion of CCND1. These results suggest that the focal
adhesion pathway and actin cytoskeleton are regulated
in part by CCND1 in PDAC cells. Correlation between
CCND1 overexpression and cellular migration was
demonstrated previously in cyclin D1
-/- MEFS [49].
While our work was under revisions, another group
demonstrated that a reduction in CCND1 protein results
in decreased invasiveness of PDAC cells further
strengthening the findings of the current study [50].
We have identified several CCND1 targets with a role
in cell adhesion, including platelet-derived growth factor
alpha (PDGFA) whose mRNA expression was affected in
two PDAC cells lines with downregulated CCND1
levels. Recent report suggested that PDGFA overexpres-
sion in PDA patients correlates with lower survival rate
[51]. In addition, Imatinib mesylate (STI571), an inhibi-
tor of alpha- and beta-platelet-derived growth factor
receptors (PDGFR) has recently been tested in clinical
trials against pancreatic cancer [52]. The relationship
between CCND1 and PDGFA signalling pathway war-
rants further examination, especially for their possible
cooperative mechanisms to promote the invasiveness of
PDAC cells.
Although to a lesser extent than CCND1, CCND3
knockdown also resulted in decreased migration through
collagen type IV in BxPC3 and HPAC cell lines suggest-
ing that D type cyclins might have overlapping roles in
cellular migration. The extent of CCND1/CCND3
effects on cellular migration appears to be cell type
specific.
Decreases in CCND1 levels in response to MAPK or
Akt inhibition confirmed a stronger response of CCND1
to the receptor tyrosine kinase (RTK) signaling pathways
in PDAC than CCND3. Although current evidence sug-
gests primarily that mitogenic signaling regulates D-
cyclins in a unidirectional pathway to activate E2F-
dependent activation of cell cycle progression, consistent
with our findings, Ginsberg et al. demonstrated a possi-
ble feedback loop whereupon E2F gene targets include
effectors of the MAPK and Akt pathway in osteosar-
coma cells [53,54]. We observed that selective E2F gene
targets depend on specific D-type cyclin regulation.
Conclusions
In this manuscript we show that the loss of cell prolif-
eration in PDAC cell lines is more pronounced follow-
ing cyclin D3 suppression compared to that of cyclin
D1. While cyclin D3 associated gene expression was
enriched for cell cycle processes, cyclin D1 associated
expression changes showed greater association with
focal adhesion/actin cytoskeleton, MAPK and NFB sig-
naling. We demonstrated that cyclin D1 has a role in
promotion of cell mobility which is consistent with
cyclin D1 occurring mainly in late stages of pancreatic
intraepithelial neoplastic progression, despite the early
ubiquitous inactivation of p16.
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Page 12 of 15Additional file 1: Supplementary Table 1. Primers for Real-time PCR of
selected genes downregulated by CCND1 or CCND3 siRNA treatment
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S1.DOC]
Additional file 2: Supplementary Figure 1. Quantification of western
blots in Figure 1. Values are means ± SEM of at least three Relative
Intensities compared to GAPDH standard control in each blot. An asterisk
represents statistically significant value calculated by Student t test (P <
0.01).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S2.DOC]
Additional file 3: Supplementary Figure 2. Pancreatic cancer cell
lines with suppressed D-cyclins were rapidly lost in cell culture.( A )
Proportions of YFP-labeled cyclin D1 (shD1_1) or cyclin D3 (shD3_1)
suppressed BxPC3, HPAC and PANC1 cells were measured over 20 days
compared with control vector (shNS) transduced cells. Asterisks designate
significant differences between test samples and control (p-value <
0.001; two-way RM ANOVA and Bonferroni posttests). Double asterisks
designate significant differences between pairs (brackets). (B) Cell viability
was measured by a presence of mitochondrial membrane potential
labeled with DiIC1(5) and exclusion of propidium iodide 5 days post
transduction, using a flow cytometry-based assay.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S3.DOC]
Additional file 4: Supplementary Figure 3. D-cyclin shRNA stable
expression in PANC1 cells. (A) Western blots show decreased levels of
cyclin D1 and cyclin D3 as a result of shD1_2 and shD3_2 shRNA
expression, respectively. (B) Growth curves for the PANC1 cells were
determined by cell counts at day 0, 3, 4, 5 and 6. Values are mean ± SD
cell number.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S4.DOC]
Additional file 5: Supplementary Table 2A-2C. List of
downregulated and upregulated genes in common with both D1
and D3 cyclin knockdown. Probe sets listed are altered at least 2-fold
downregulated (green) or upregulated (red) compared with the non-
specific siRNA experiment in control cells, and were mapped to UniGene,
Entrez Gene and SwissProt. Genes/proteins that were matched to
protein-protein interactions (PPIs) in I
2D ver. 1.7 appear in boldface in
SwissProt ID
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S5.DOC]
Additional file 6: Supplementary Table 3. The numbers of genes (all
targets) uniquely and commonly altered in D1- or D3-cyclin
suppressed PANC1 cells. The numbers of genes (all targets) uniquely or
commonly altered in D1- or D3-cyclin suppressed PANC1 cells. Values are
the number of genes functionally annotated in each of the three
resources (PPI networks, GO and KEGG). Up and down deregulated gene
expressions are common or unique to a D-type cyclin siRNA. The
number of functionally annotated genes is increased when targets as
well as their immediate interacting proteins are considered. Not
applicable (NA).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S6.XLS]
Additional file 7: Supplementary Table 4A-4D. Functional
annotation of deregulated common target genes in D1- or D3-
cyclin suppressed cells and their interacting proteins obtained from
protein interaction database I
2D ver. 1.7.. Significant associations with
GO biological processes are shown for common deregulated genes in
either D1 or D3 cyclin siRNA-treated cells. Listed are terms where values
of enrichment >2 and p-value < 0.05. Enrichment and FDR are as per
GoMiner analysis (GO database version 2007-06) described in Materials
and Methods.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S7.DOC]
Additional file 8: Supplementary Table 5. KEGG functional
annotation of deregulated target genes in D1- or D3-cyclin
suppressed cells and their interacting proteins obtained from
protein interaction database I
2D ver. 1.7. ([23]; http://ophid.utoronto.
ca/i2d). Listed are number of genes mapped to a selection of 38 cancer
and signaling KEGG pathways; common target genes are downregulated
(down) or upregulated (up) by either D1- or D3-cyclin siRNA treatment
(D1/D3). Following are deregulated genes (down or up) unique to either
cyclin D1 (D1) or cyclin D3 (D3) siRNA treatment. A significant
enrichment (red highlighted) for KEGG pathway cell cycle proteins was
found for cyclin D3 downregulated gene targets (p = 0.0048). PPI
network analysis showed significant enrichments (red highlighted) of two
KEGG pathways: p53 signaling (p = 0.0008) and cell cycle (p = 0.004).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S8.DOC]
Additional file 9: Supplementary Figure 4. Quantification of western
blots in Figure 6. Values are means ± SEM of at least three relative
intensities compared to untreated control in each blot. An asterisk
represents statistically significant value calculated by Student t-test (P <
0.01).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-24-
S9.DOC]
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